Beijing Immunochina Pharmaceuticals Co., Ltd.

Established in 2015 and based in Beijing, China, Beijing Immunochina Pharmaceuticals Co. , Ltd. operates as an immune cell therapy institution that provides cancer diagnosis and treatment services based on immune cell therapy. It has manufacturing facilities and production and testing facilities, which meet the regulations of China, the US, and the EU.

The expert team of the company are from Peking University Third Hospital, Peking University Institute of Hematology and Peking University Cancer Hospital. In 2020, its product IM19 for lymphocytic leukemia and non-Hodgkin's lymphoma received two IND approvals. In January 2025, the company closed a series E funding. The company mainly engages in the research and development of malignant tumor treatment using gene cell drug technology.

It develops gene vector scaling platform, T cell research, and scaling platform, and gene and cell drug analysis platform. Its R&D pipeline covers hematological tumors and solid tumors, including lymphoma, leukemia, liver cancer and colorectal cancer. Besides, the company is developing IM19 for diffuse large B cell lymphomas, and mantle cell lymphoma, IM21 for multiple myeloma, and IM23 for acute myeloid leukemia. The company generates revenue by developing tumor treatment drugs for liver cancer, stomach cancer, pancreatic cancer and other diseases.

The company will use the series E funding to support the commercialization of the new CAR-T drug IM19, accelerate the research and development and clinical progress of drugs in fields including blood tumors, solid tumors and autoimmune diseases, and promote the construction of a large-scale GMP production and manufacturing base.